We are pleased to share with you an exclusive interview conducted with Neoleukin’s Daniel-Adriano Silva (Vice President & Head of Research) and Carl Walkey (Vice President, Corporate Development).
As leaders of one of the most exciting companies in the cytokine therapeutic industry, Daniel and Carl share their insights into the current hurdles facing this space and how we can move the Next Generation of Cytokine Therapeutics forward.
Topics covered include:
How do Neoleukin’s de novo protein therapeutics avoid toxicity?
What are the biggest opportunities available to those developing cytokine therapeutics?
What is the biggest limiting factor holding back the industry, and how are companies like Neoleukin working to overcome this?